Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia
NCT01088763
Terminated
This phase I/II clinical trial is studying the side effects and best dose of gamma-secretase inhibitor RO4929097 and to see how well it works in treating young patients with relapsed or refractory solid tumors, CNS tumors, lymphoma, or T-cell leukemia. Gamma-secretase inhibitor RO4929097 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Gender:
ALL
Ages:
Between 1 year and 21 years
Trial Updated:
11/04/2014
Locations: Baylor College of Medicine, Houston, Texas
Conditions: Childhood Atypical Teratoid/Rhabdoid Tumor, Childhood Central Nervous System Choriocarcinoma, Childhood Central Nervous System Germinoma, Childhood Central Nervous System Mixed Germ Cell Tumor, Childhood Central Nervous System Teratoma, Childhood Central Nervous System Yolk Sac Tumor, Childhood Choroid Plexus Tumor, Childhood Craniopharyngioma, Childhood Ependymoblastoma, Childhood Grade I Meningioma, Childhood Grade II Meningioma, Childhood Grade III Meningioma, Childhood Infratentorial Ependymoma, Childhood Medulloepithelioma, Childhood Mixed Glioma, Childhood Oligodendroglioma, Childhood Supratentorial Ependymoma, Gonadotroph Adenoma, Pituitary Basophilic Adenoma, Pituitary Chromophobe Adenoma, Pituitary Eosinophilic Adenoma, Prolactin Secreting Adenoma, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Anaplastic Large Cell Lymphoma, Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Central Nervous System Embryonal Tumor, Recurrent Childhood Cerebellar Astrocytoma, Recurrent Childhood Cerebral Astrocytoma, Recurrent Childhood Ependymoma, Recurrent Childhood Grade III Lymphomatoid Granulomatosis, Recurrent Childhood Large Cell Lymphoma, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Medulloblastoma, Recurrent Childhood Pineoblastoma, Recurrent Childhood Small Noncleaved Cell Lymphoma, Recurrent Childhood Spinal Cord Neoplasm, Recurrent Childhood Subependymal Giant Cell Astrocytoma, Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor, Recurrent Childhood Visual Pathway and Hypothalamic Glioma, Recurrent Childhood Visual Pathway Glioma, Recurrent Pituitary Tumor, Recurrent/Refractory Childhood Hodgkin Lymphoma, T-cell Childhood Acute Lymphoblastic Leukemia, T-cell Large Granular Lymphocyte Leukemia, TSH Secreting Adenoma, Unspecified Childhood Solid Tumor, Protocol Specific
Register for Updates
Study of SGN-40, Lenalidomide, and Dexamethasone in Patients With Multiple Myeloma
NCT00525447
Completed
This is a Phase I, open-label, multi-dose trial to define the MTD and tolerability of a regimen including lenalidomide, dexamethasone, and intravenous SGN-40 in patients with relapsed multiple myeloma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/07/2014
Locations: Baylor University Medical Center, Dallas, Texas
Conditions: Multiple Myeloma
Register for Updates
A Study to Assess Treatment With 2 Different Dosing Schedules of Trabectidin Administered to Patients With Advanced Cancer
NCT00060944
Completed
The purpose of this study is to test the safety and effectiveness of an investigational chemotherapy agent in patients with types of advanced cancer referred to as liposarcoma or leiomyosarcoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/28/2014
Locations: Not set, Houston, Texas
Conditions: Liposarcoma, Leiomyosarcoma
Register for Updates
Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Lymphocytic Leukemia
NCT00003671
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating children who have newly diagnosed acute lymphocytic leukemia.
Gender:
ALL
Ages:
18 years and below
Trial Updated:
07/24/2014
Locations: Medical City Dallas Hospital, Dallas, Texas +6 locations
Conditions: Leukemia
Register for Updates
Combination Chemotherapy in Treating Children With Very High Risk Acute Lymphocytic Leukemia
NCT00003783
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug and combining drugs in different ways may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of chemotherapy in treating children who have very high risk acute lymphocytic leukemia.
Gender:
ALL
Ages:
17 years and below
Trial Updated:
07/24/2014
Locations: Medical City Dallas Hospital, Dallas, Texas +6 locations
Conditions: Leukemia
Register for Updates
Combination Chemotherapy, Bone Marrow Transplantation, and Radiation Therapy in Treating Infants With Acute Lymphoblastic Leukemia
NCT00002785
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. Bone marrow transplantation may allow the doctor to give higher doses of chemotherapy and kill more cancer cells. Radiation therapy uses high-energy x-rays to damage cancer cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy, bone marrow transplantation, and radiation therapy in treatin... Read More
Gender:
ALL
Ages:
1 year and below
Trial Updated:
07/23/2014
Locations: University of Texas - MD Anderson Cancer Center, Houston, Texas
Conditions: Leukemia
Register for Updates
Combination Chemotherapy in Treating Children With Stage III or Stage IV Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia
NCT00003217
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase I trial to study the effectiveness of combination chemotherapy consisting of methotrexate and cyclophosphamide in treating children who have stage III or stage IV non-Hodgkin's lymphoma or acute lymphoblastic leukemia.
Gender:
ALL
Ages:
21 years and below
Trial Updated:
07/23/2014
Locations: Simmons Cancer Center - Dallas, Dallas, Texas +1 locations
Conditions: Leukemia, Lymphoma
Register for Updates
Diphenhydramine, Lorazepam, and Dexamethasone in Treating Nausea and Vomiting Caused By Chemotherapy
NCT00429702
Terminated
RATIONALE: Diphenhydramine, lorazepam, and dexamethasone may help lessen or prevent nausea and vomiting in patients treated with chemotherapy. It is not yet known whether diphenhydramine, lorazepam, and dexamethasone are more effective than standard therapy in treating nausea and vomiting caused by chemotherapy. PURPOSE: This randomized phase II trial is studying diphenhydramine, lorazepam, and dexamethasone to see how well they work compared with standard therapy in treating nausea and vomitin... Read More
Gender:
ALL
Ages:
Between 8 years and 18 years
Trial Updated:
06/26/2014
Locations: CHRISTUS Santa Rosa Children's Hospital, San Antonio, Texas
Conditions: Nausea, Vomiting, Unspecified Childhood Solid Tumor, Protocol Specific
Register for Updates
An Efficacy and Safety Study for Yondelis (Trabectedin) in Patients With Advanced Relapsed Ovarian Cancer
NCT00113607
Completed
The purpose of the study is to compare the progression-free survival (PFS) of the combination of trabectedin + DOXIL with DOXIL monotherapy in patients with ovarian cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
06/18/2014
Locations: Not set, Dallas, Texas +1 locations
Conditions: Ovarian Cancer
Register for Updates
Papillary Serous Carcinoma of the Endometrium
NCT00515073
Completed
Primary Objectives: * To evaluate the results of Paclitaxel and pelvic radiation in pelvic confined papillary serous carcinoma of the endometrium for both local control and overall survival. * To evaluate the toxicity of Paclitaxel and pelvic radiation. * To collect and evaluate patients' quality of life/symptom assessment data.
Gender:
FEMALE
Ages:
All
Trial Updated:
05/30/2014
Locations: UT MD Anderson Cancer Center, Houston, Texas
Conditions: Endometrial Cancer
Register for Updates
An Efficacy and Safety Study of Siltuximab in Participants With Relapsed or Refractory Multiple Myeloma
NCT00402181
Completed
The purpose of this study is to evaluate the safety and efficacy of siltuximab in participants with relapsed (the return of a disease or the signs and symptoms of a disease after a period of improvement.) or refractory (cancer that does not respond to treatment) multiple myeloma (a type of cancer that begins in plasma cells \[white blood cells that produce antibodies\]).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/13/2014
Locations: Not set, Houston, Texas
Conditions: Multiple Myeloma
Register for Updates
Dexamethasone With or Without Thalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma
NCT00033332
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Thalidomide may stop the growth of cancer by stopping blood flow to the tumor. Combining dexamethasone and thalidomide may kill more cancer cells. It is not yet known whether dexamethasone is more effective with or without thalidomide in treating multiple myeloma. PURPOSE: Randomized phase III trial to determine the effectiveness of dexamethasone with or without thalidomide i... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/02/2014
Locations: CCOP - Scott and White Hospital, Temple, Texas
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Register for Updates